Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2-transfected CIK cells
- Development stage
- Unknown
- Lead developer
- University of Bonn
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
IL-2-transfected CIK cells are an autologous cell therapy consisting of cytokine-induced killer (CIK) cells—a heterogeneous population of T lymphocytes with natural killer (NK) cell-like activity—genetically modified to express interleukin-2 (IL-2). CIK cells are typically generated from peripheral blood mononuclear cells (PBMCs) through ex vivo stimulation with IFN-gamma, anti-CD3 antibodies, and IL-2. In this specific formulation, the cells are transfected (often via electroporation with a plasmid) with the IL-2 gene to provide a localized, autocrine source of the cytokine, thereby enhancing the cells' proliferation, survival, and cytotoxic activity against tumor cells without the systemic toxicity associated with high-dose IL-2 administration. This approach has been investigated in Phase I trials for metastatic renal cell carcinoma, colorectal carcinoma, and lymphoma.
- Other names
- IL-2-transfected cytokine-induced killer cellsIL2-transfected cytokine-induced killer cellsIL 2-transfected cytokine-induced killer cellsautologous IL-2-transfected CIK cells
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on IL-2-transfected CIK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2-transfected CIK cells.